2Herrero JI, Lorenzo M, Quiroga J, et al. De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival [J]. Liver Transpl,2005,11(1): 89-97.
4Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation [J]. Transplantation,2002,74(7): 1007-1012.
5McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus[J]. Liver Transpl,2001,7(8):701-708.
6Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo [J]. Transplantation, 1994,57(8): 1231 - 1237.
7Yao FY, Gautam M, Palese C, et al. De novo malignancies following liver transplantation: a case-control study with long-term follow-up[J]. Clin Transplant,2006,20(5): 617-623.
8Patapis P, Irani S, Mirza DF, et al. Outcome of graft function and pregnancy following liver transplantation[J]. Transplant Proc,1997,29(1-2):1565-1566.
9Hsu HT, Hwang SL, Lee PH, et al. Impact of liver donation on quality of life and physical and psychological distress[J]. Transplant Proc,2006,38(7):2102-2105.
二级参考文献7
1Samuel D, Muller R, Alexander G, et al. Liver transplantationin European patients with the hepatitis B surface antigen. N Engl J Med, 1993, 329.. 1842-1847.
2Perrillo RP, Wright T, Rakela J, et al. A multieenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology, 2001, 33:424-432.
3Marcellin P, Samuel D, Areias J, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end stage liver disease Hepatology, 1994, 19:6-15.
4Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B related liver disease Hepatology, 2002, 35:1528-1535.
5Seehofer D, Raues N, Steinmuller T, et al. Combination prophylaxis with hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of preatransplant lamivudine resistane. Z Gastroenterol, 2002, 40: 795-799.
6Han SH, Martin p, Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-termprophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl, 2003, 9: 182-187.
7Sousa JM, Pareja F, Serrano J, et al. Comparison between levels of anti-HBs with a fixed administration dose of HBIg and a combination of HBIg and lamivudine for the prophylaxis of hepatitis B after liver transplantation. Transplant Proc, 2003, 35: 723-724.